| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|---|
Operating expenses: | ||||||||
Research and development | ||||||||
41,414 | 42,596 | 40,148 | 35,676 | 24,983 | 25,872 | 18,857 | 7,930 | 2,624 |
In process research and development | ||||||||
2,805 | 1,600 | 0 | 1,000 | 1,000 | 0 | 8,261 | 20,500 | 20,898 |
General and administrative | ||||||||
10,748 | 11,591 | 9,838 | 9,673 | 8,034 | 13,935 | 22,906 | 4,606 | 2,604 |
Total operating expenses | ||||||||
54,967 | 55,787 | 49,986 | 46,349 | 34,017 | 39,807 | 50,024 | 33,036 | 26,126 |
Loss from operations | ||||||||
-54,967 | -55,787 | -49,986 | -46,349 | -34,017 | -39,807 | -50,024 | -33,036 | -26,126 |
Interest income | ||||||||
- | - | - | - | - | - | - | - | 89 |
Other income, net | ||||||||
893 | 1,089 | 1,486 | 1,851 | 1,406 | 1,013 | 622 | 300 | 89 |
Net loss | ||||||||
-54,074 | -54,698 | -48,500 | -44,498 | -32,611 | -38,794 | -49,402 | -32,736 | -26,037 |
Other comprehensive income: | ||||||||
Foreign currency translation, net of tax | ||||||||
-87 | - | - | - | - | - | - | - | - |
Other comprehensive income (loss) | ||||||||
-763 | -70 | -168 | 417 | 140 | - | 232 | 3 | - |
Unrealized gain (loss) on marketable securities, net of tax | ||||||||
-676 | -58 | -168 | 417 | 140 | - | 232 | 3 | - |
Comprehensive loss | ||||||||
-54,837 | -54,768 | -48,668 | -44,081 | -32,471 | -39,090 | -49,170 | -32,733 | -26,037 |
Net loss per share, basic and diluted | ||||||||
-0.87 | -0.85 | -0.80 | -0.74 | -0.90 | -4.76 | -7.69 | -5.65 | -4.49 |
Weighted average common shares outstanding, basic and diluted | ||||||||
61,890 | 61,622 | 60,755 | 60,265 | 36,317 | 8,003 | 6,423 | 5,795 | 5,797 |